Rishi P Singh, Thais F Conti, Sumit Sharma, Katherine E Talcott, Justin C Muste, Matthew W Russell, Andrew X Chen, Kanika Seth, Amogh I Iyer, Carolina C S Valentim, Anna K Wu, Blanche L Kuo, Aneesha Kalur, Resya Sastry, Grant L Hom, Collin A Rich
Journal: Ophthalmic surgery, lasers & imaging retina 2023;54(1):24-31
PMID: 36626211
PURPOSE
Oxidative stress-induced mitochondrial dysfunction is implicated in the pathogenesis of age-related macular degeneration (AMD). Oxidized mitochondrial flavoprotein fluorescence (FPF) may serve as a quantifiable biomarker of oxidative stress, reported as either mean score for the entire image (intensity) or variability (heterogeneity). This study examines FPF intensity and heterogeneity across a large patient cohort of various Beckman stages of AMD.
METHODS
This study enrolled patients with isolated AMD and healthy control patients with no retinopathy between 2018 and 2021. Multivariate logistic regression analysis included stage of AMD, age, gender, ethnicity, and smoking status. Analysis of Variance test compared mean FPF intensity and heterogeneity between disease states.
RESULTS
Four hundred fifty-six eyes (228 AMD eyes, 228 age-matched control eyes) were included in the final multivariate analysis. Intermediate, geographic atrophy (GA), and neovascular AMD correlated with significantly increased FPF intensity ( < 0.001, respectively), while all AMD stages correlated with increased FPF heterogeneity ( < 0.001, respectively). FPF intensity and heterogeneity were significant negative predictors of visual acuity ( = 0.018 and 0.024, respectively).
CONCLUSIONS
This prospective observational study further implicates mitochondrial damage in AMD pathophysiology. Long-term clinical trials will be needed to examine the predictive role of FPF imaging in patients over time. .
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.